Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 28, 2012, Pages 11306-11311

  Sunshine, Sarah B ^a   Dallabrida, Susan M ^a   Durand, Ellen ^a   Ismail, Nesreen S ^a   Bazinet, Lauren ^a   Birsner, Amy E ^a   Sohn, Regina ^b   Ikeda, Sadakatsu ^a   Pu, William T ^a   Kulke, Matthew H ^c   Javaherian, Kashi ^a   Zurakowski, David ^a   Folkman, Judah M ^a   Rupnick, Maria ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN G; NITRATE; NITRIC OXIDE; NITRITE; RECOMBINANT ENDOSTATIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CANCER PATIENT; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; MALE; MOUSE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; BLOOD PRESSURE; CLINICAL TRIALS, PHASE II AS TOPIC; ENDOSTATINS; FEMALE; HEART; HUMANS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 84863885816     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203275109     Document Type: Article

References (54)

1. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186.
2. Goff MJ, et al. (2007) Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27:432-438. (Pubitemid 46624282)
3. Rajappa M, Saxena P, Kaur J (2010) Ocular angiogenesis: Mechanisms and recent advances in therapy. Adv Clin Chem 50:103-121.
4. Folkman J (2006) Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 312:594-607.
5. Yang JC, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434. (Pubitemid 36910021)
6. Miller K, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676.
7. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
8. Sandler A, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for nonsmall- cell lung cancer. N Engl J Med 355:2542-2550. (Pubitemid 44917502)
9. Grothey A, et al. (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334.
10. Bhargava P (2009) VEGF kinase inhibitors: How do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297:R1-R5.
11. Escudier B, et al. (2007) Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125-134. (Pubitemid 46089673)
12. Motzer RJ, et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:LBA3.
13. Veronese ML, et al. (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369. (Pubitemid 46621999)
14. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9:117-123.
15. Langenberg M, et al. (2009) Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 27(36):6152-6159.
16. Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, discussion 980-982.
17. Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63:1475-1478. (Pubitemid 44547561)
18. Chu TF, et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019. (Pubitemid 350236338)
19. Humphreys BD, Atkins MB (2009) Rapid development of hypertension by sorafenib: Toxicity or target? Clin Cancer Res 15:5947-5949.
20. Barter PJ, et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122. (Pubitemid 350146106)
21. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274: H1054-H1058.
22. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7:359-371.
23. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652-658.
24. Henry TD, et al.; VIVA Investigators (2003) The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107:1359-1365. (Pubitemid 36350732)
25. Oh SP, et al. (1994) Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91:4229-4233. (Pubitemid 24143406)
26. Rehn M, Pihlajaniemi T (1994) Alpha 1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci USA 91:4234-4238.
27. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407. (Pubitemid 28027321)
28. O'Reilly MS, et al. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285. (Pubitemid 28015876)
29. Wenzel D, et al. (2006) Endostatin, the proteolytic fragment of collagen XVIII, induces vasorelaxation. Circ Res 98:1203-1211. (Pubitemid 43948107)
30. Li C, Harris MB, Venema VJ, Venema RC (2005) Endostatin induces acute endothelial nitric oxide and prostacyclin release. Biochem Biophys Res Commun 329:873-878. (Pubitemid 40341359)
31. Yang Q, Rasmussen SA, Friedman JM (2002) Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 359: 1019-1025. (Pubitemid 34286539)
32. Baek KH, et al. (2009) Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459:1126-1130.
33. Richards BW, Enver F (1979) Blood pressure in Down's syndrome. J Ment Defic Res 23: 123-135. (Pubitemid 9252818)
34. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812. (Pubitemid 29291347)
35. Zorick TS, et al. (2001) High serum endostatin levels in Down syndrome: Implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 9:811-814. (Pubitemid 34030710)
36. Huang PL, et al. (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242.
37. Khraibi AA (1991) Association between disturbances in the immune system and hypertension. Am J Hypertens 4:635-641.
38. Gasparini G, et al. (1999) Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5:101-111. (Pubitemid 29169299)
39. Miller KD, et al. (2005) A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11:3369-3376. (Pubitemid 40627889)
40. Miles D, et al. (2010) Phase III study of bevacizumab plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247.
41. Robert N, et al. (2011) RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260.
42. Mir O, Ropert S, Alexandre J, Goldwasser F (2009) Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20:967-970.
43. Lee TY, et al. (2008) Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14:1487-1493.
44. Urbich C, et al. (2002) Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16:706-708.
45. Tanimoto T, Jin ZG, Berk BC (2002) Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 277: 42997-43001. (Pubitemid 35285679)
46. Gélinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG (2002) Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathways. Br J Pharmacol 137:1021-1030. (Pubitemid 35440742)
47. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485. (Pubitemid 46809172)
48. Staudt A, et al. (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106:2448-2453. (Pubitemid 35278800)
49. Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A (2007) Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 49:1684-1692. (Pubitemid 46589923)
50. Johns C, Gavras I, Handy DE, Salomao A, Gavras H (1996) Models of experimental hypertension in mice. Hypertension 28:1064-1069. (Pubitemid 26415825)
51. Fukai N, et al. (2002) Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 21:1535-1544. (Pubitemid 34614610)
52. Marneros AG, Olsen BR (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19:716-728. (Pubitemid 40617376)
53. Sund M, et al. (2005) Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102:2934-2939. (Pubitemid 40299894)
54. Kulke MH, et al. (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555-3561. (Pubitemid 46630526)